A Phase 1 interventional study of LY3316531 - IV and LY3316531 - SC in Psoriasis, sponsored by Eli Lilly and Company. Completed at 2 sites in United States. Open to participants aged 18 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-09-21.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 35 studies in Psoriasis by Eli Lilly and Company — 1 open to participants now, 1 under way, none of them phase 3. Psoriasis · Eli Lilly and Company.
Among the 35 studies in Psoriasis by Eli Lilly and Company, this one is the 23rd largest by enrollment, is one of 6 that started in 2018, is one of 9 in phase 1, and was the 21st registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →1 of the 35 studies in Psoriasis by Eli Lilly and Company is open now, in 1 country. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
35 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 6 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 63 is below the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 162 across the 35 interventional studies. Of the 34 that completed or were terminated, 28 (82%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 536 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 35 studies in Psoriasis by Eli Lilly and Company, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate how well LY3316531 is tolerated and what side effects may occur in healthy participants and participants with psoriasis. The study drug will be administered either subcutaneously (SC) (under the skin) or intravenously (IV) (into a vein in the arm).
This is a three-part study. Participants will enroll in only one part. Parts A and B are for healthy participants and Part C is for participants with psoriasis. Participation could last between 16 and 57 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Healthy Participants
Psoriasis Participants:
Exclusion Criteria:
Healthy and Psoriasis Participants
Psoriasis Participants Only:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received single doses of 3 milligrams (mg), 15 mg, 75 mg, 300 mg, 900 mg, or 2000 mg LY3316531 administered Intravenously (IV), or 300 mg LY3316531 administered Subcutaneously (SC).
Drug: LY3316531 - IV · Drug: LY3316531 - SC
Placebo matching LY3316531 administered IV.
Drug: Placebo - IV
Participants received 3 doses of 2000 mg LY3316531 administered IV (1 dose every 4 weeks).
Drug: LY3316531 - IV
Placebo matching LY3316531 administered IV.
Drug: Placebo - IV
Participants with psoriasis received single doses of 300 mg LY3316531 administered IV.
Drug: LY3316531 - IV
Administered IV.
Administered SC.
Administered IV.
Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality is reported in the Reported Adverse Events module. An SAE is any adverse event from this study that results in 1 of the following: 1. Death 2. Initial or prolonged inpatient hospitalization 3. A life-threatening experience (that is, immediate risk of dying) 4. Persistent or significant disability/incapacity 5. Congenital anomaly/birth defect 6. Important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the subject or may require intervention to prevent 1 of the other outcomes listed in the definition above.
Time frame: Pre-dose up to 1 year after administration of study drug
Part A: Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3316531
PK: Cmax of LY3316531. Under time frame, hours was abbreviated as "hrs."
Time frame: Pre-dose, Days 1 (End of infusion [IV], 2 hrs after start of infusion [IV], 6 hrs after start of infusion [IV] or injection [SC]), 2 (24 hrs after start of infusion [IV] or injection [SC]), 4, 8, 11 (SC only), 15, 22, 29, 43, 57, 71, 85 post- dose
Part B: Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3316531
PK: Cmax of LY3316531 following the Day 57 dose.
Time frame: Days 57 (Pre-dose, end of infusion), 58, 60, 64, 67, 71, 78, and 85
Part C: Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3316531
PK: Cmax of LY3316531.
Time frame: Pre-dose, Days 1 (End of infusion, 2 hrs after start of infusion, 6 hrs after start of infusion), 2 (24 hrs after start of infusion), 4, 8, 15, 22, 29, 43, 57, 71, 85, and 113 post-dose
Part A: PK: Area Under the Concentration Versus Time Curve (AUC) of LY3316531 From Time Zero to Infinity - AUC(0-∞)
Area Under the Concentration Versus Time Curve (AUC) of LY3316531 From Time Zero to Infinity - AUC(0-∞).
Time frame: Pre-dose, Days 1 (End of infusion [IV], 2 hrs after start of infusion [IV], 6 hrs after start of infusion [IV] or injection [SC]), 2 (24 hrs after start of infusion [IV] or injection [SC]), 4, 8, 11 (SC only), 15, 22, 29, 43, 57, 71, 85 post- dose
Part B: PK: Area Under the Concentration Versus Time Curve (AUC) of LY3316531 Over the Dosing Interval (Tau) - AUCtau
AUC of LY3316531 over the dosing interval (tau = 672 h = 28 days) following the Day 57 dose.
Time frame: Days 57 (Pre-dose, end of infusion), 58, 60, 64, 67, 71, 78, and 85
Part C: PK: Area Under the Concentration Versus Time Curve (AUC) of LY3316531 From Time Zero to Infinity - AUC(0-∞)
Area Under the Concentration Versus Time Curve (AUC) of LY3316531 From Time Zero to Infinity - AUC(0-∞).
Time frame: Pre-dose, Days 1 (End of infusion, 2 hrs after start of infusion, 6 hrs after start of infusion), 2 (24 hrs after start of infusion), 4, 8, 15, 22, 29, 43, 57, 71, 85, and 113 post-dose
Study consists of three parts: * Part A (Single-Ascending Dose (SAD) in healthy participants) * Part B (Multiple-dose in healthy participants) and * Part C (Single dose in psoriasis participants)
| Milestone | Placebo - Part A | 3 mg LY3316531 IV - Part A | 15 mg LY3316531 IV - Part A | 75 mg LY3316531 IV - Part A | 300 mg LY3316531 IV - Part A | 300 mg LY3316531 SC- Part A | 900 mg LY3316531 IV - Part A | 2000 mg LY3316531 IV - Part A | Placebo - Part B | 2000 mg LY3316531 IV - Part B | 300 mg LY3316531 IV - Part C |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 11 | 3 | 3 | 6 | 6 | 6 | 6 | 6 | 2 | 6 | 8 |
| Completed | 10 | 3 | 3 | 6 | 6 | 6 | 6 | 6 | 2 | 5 | 8 |
| Not completed | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
A summary of SAEs and other non-serious adverse events (AEs), regardless of causality is reported in the Reported Adverse Events module. An SAE is any adverse event from this study that results in 1 of the following: 1. Death 2. Initial or prolonged inpatient hospitalization 3. A life-threatening experience (that is, immediate risk of dying) 4. Persistent or significant disability/incapacity 5. Congenital anomaly/birth defect 6. Important medical events that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the subject or may require intervention to prevent 1 of the other outcomes listed in the definition above.
| Participants | Placebo - Part A | 3 mg LY3316531 IV - Part A | 15 mg LY3316531 IV - Part A | 75 mg LY3316531 IV - Part A | 300 mg LY3316531 IV - Part A | 300 mg LY3316531 SC- Part A | 900 mg LY3316531 IV - Part A | 2000 mg LY3316531 IV - Part A | Placebo - Part B | 2000 mg LY3316531 IV - Part B | 300 mg LY3316531 IV - Part C |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
PK: Cmax of LY3316531. Under time frame, hours was abbreviated as "hrs."
| micrograms per milliliter (μg/mL) | 3 mg LY3316531 IV - Part A | 15 mg LY3316531 IV - Part A | 75 mg LY3316531 IV - Part A | 300 mg LY3316531 IV - Part A | 300 mg LY3316531 SC- Part A | 900 mg LY3316531 IV - Part A | 2000 mg LY3316531 IV - Part A |
|---|---|---|---|---|---|---|---|
| Part A: Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3316531 | 1.27 ± 18 | 9.94 ± 26 | 32.7 ± 22 | 115 ± 11 | 27.2 ± 30 | 453 ± 14 | 808 ± 15 |
PK: Cmax of LY3316531 following the Day 57 dose.
| μg/mL | 2000 mg LY3316531 IV - Part B |
|---|---|
| Part B: Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3316531 | 876 ± 14 |
PK: Cmax of LY3316531.
| μg/mL | 300 mg LY3316531 IV - Part C |
|---|---|
| Part C: Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3316531 | 124 ± 19 |
Area Under the Concentration Versus Time Curve (AUC) of LY3316531 From Time Zero to Infinity - AUC(0-∞).
| micrograms*hours per milliliter(μg*h/mL) | 3 mg LY3316531 IV - Part A | 15 mg LY3316531 IV - Part A | 75 mg LY3316531 IV - Part A | 300 mg LY3316531 IV - Part A | 300 mg LY3316531 SC- Part A | 900 mg LY3316531 IV - Part A | 2000 mg LY3316531 IV - Part A |
|---|---|---|---|---|---|---|---|
| Part A: PK: Area Under the Concentration Versus Time Curve (AUC) of LY3316531 From Time Zero to Infinity - AUC(0-∞) | 401 ± 7 | 3050 ± 23 | 12,700 ± 19 | 46,900 ± 10 | 25,800 ± 27 | 181,000 ± 25 | 319,000 ± 31 |
AUC of LY3316531 over the dosing interval (tau = 672 h = 28 days) following the Day 57 dose.
| μg*h/mL | 2000 mg LY3316531 IV - Part B |
|---|---|
| Part B: PK: Area Under the Concentration Versus Time Curve (AUC) of LY3316531 Over the Dosing Interval (Tau) - AUCtau | 258,000 ± 2 |
Area Under the Concentration Versus Time Curve (AUC) of LY3316531 From Time Zero to Infinity - AUC(0-∞).
| μg*h/mL | 300 mg LY3316531 IV - Part C |
|---|---|
| Part C: PK: Area Under the Concentration Versus Time Curve (AUC) of LY3316531 From Time Zero to Infinity - AUC(0-∞) | 39,500 ± 28 |
Collected over Up To 1 Year. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo - Part A | 0/11 (0%) | 0/11 (0%) | 5/11 (45.5%) |
| 3 mg LY3316531 IV - Part A | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) |
| 15 mg LY3316531 IV - Part A | 0/3 (0%) | 0/3 (0%) | 1/3 (33.3%) |
| 75 mg LY3316531 IV - Part A | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| 300 mg LY3316531 IV - Part A | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| 300 mg LY3316531 SC- Part A | 0/6 (0%) | 0/6 (0%) | 5/6 (83.3%) |
| 900 mg LY3316531 IV - Part A | 0/6 (0%) | 0/6 (0%) | 2/6 (33.3%) |
| 2000 mg LY3316531 IV - Part A | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Placebo - Part B | 0/2 (0%) | 0/2 (0%) | 1/2 (50%) |
| 2000 mg LY3316531 IV - Part B | 0/6 (0%) | 1/6 (16.7%) | 4/6 (66.7%) |
| 300 mg LY3316531 IV - Part C | 0/8 (0%) | 0/8 (0%) | 7/8 (87.5%) |
| Event | Placebo - Part A | 3 mg LY3316531 IV - Part A | 15 mg LY3316531 IV - Part A | 75 mg LY3316531 IV - Part A | 300 mg LY3316531 IV - Part A | 300 mg LY3316531 SC- Part A | 900 mg LY3316531 IV - Part A | 2000 mg LY3316531 IV - Part A | Placebo - Part B | 2000 mg LY3316531 IV - Part B | 300 mg LY3316531 IV - Part C |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Abscess limbInfections and infestations | 0/11 | 0/3 | 0/3 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/2 | 1/6 | 0/8 |
| Event | Placebo - Part A | 3 mg LY3316531 IV - Part A | 15 mg LY3316531 IV - Part A | 75 mg LY3316531 IV - Part A | 300 mg LY3316531 IV - Part A | 300 mg LY3316531 SC- Part A | 900 mg LY3316531 IV - Part A | 2000 mg LY3316531 IV - Part A | Placebo - Part B | 2000 mg LY3316531 IV - Part B | 300 mg LY3316531 IV - Part C |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ConstipationGastrointestinal disorders | 0/11 | 0/3 | 0/3 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/2 | 0/6 | 0/8 |
| Upper respiratory tract infectionInfections and infestations | 0/11 | 1/3 | 0/3 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 1/2 | 0/6 | 1/8 |
| Injection site erythemaGeneral disorders | 0/11 | 0/3 | 0/3 | 0/6 | 0/6 | 2/6 | 0/6 | 0/6 | 0/2 | 0/6 | 0/8 |
| LacerationInjury, poisoning and procedural complications | 0/11 | 0/3 | 1/3 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/2 | 0/6 | 0/8 |
| Musculoskeletal stiffnessMusculoskeletal and connective tissue disorders | 0/11 | 1/3 | 0/3 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/2 | 1/6 | 0/8 |
| HeadacheNervous system disorders | 2/11 | 0/3 | 0/3 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/2 | 0/6 | 0/8 |
| Chapped lipsGastrointestinal disorders | 0/11 | 0/3 | 0/3 | 1/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/2 | 0/6 | 0/8 |
| Chest painGeneral disorders | 0/11 | 0/3 | 0/3 | 0/6 | 0/6 | 0/6 | 1/6 | 0/6 | 0/2 | 0/6 | 0/8 |
| Infusion site bruisingGeneral disorders | 0/11 | 0/3 | 0/3 | 0/6 | 0/6 | 0/6 | 0/6 | 0/6 | 0/2 | 1/6 | 0/8 |
| Injection site bruisingGeneral disorders | 0/11 | 0/3 | 0/3 | 0/6 | 0/6 | 1/6 | 0/6 | 0/6 | 0/2 | 0/6 | 0/8 |
All randomized participants.
| Age, Categorical(Participants) | Placebo - Part A | 3 mg LY3316531 IV - Part A | 15 mg LY3316531 IV - Part A | 75 mg LY3316531 IV - Part A | 300 mg LY3316531 IV - Part A | 300 mg LY3316531 SC- Part A | 900 mg LY3316531 IV - Part A | 2000 mg LY3316531 IV - Part A | Placebo - Part B | 2000 mg LY3316531 IV - Part B | 300 mg LY3316531 IV - Part C | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 11 | 3 | 3 | 6 | 6 | 6 | 6 | 6 | 2 | 6 | 8 | 63 |
| >=65 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Placebo - Part A | 3 mg LY3316531 IV - Part A | 15 mg LY3316531 IV - Part A | 75 mg LY3316531 IV - Part A | 300 mg LY3316531 IV - Part A | 300 mg LY3316531 SC- Part A | 900 mg LY3316531 IV - Part A | 2000 mg LY3316531 IV - Part A | Placebo - Part B | 2000 mg LY3316531 IV - Part B | 300 mg LY3316531 IV - Part C | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 4 | 1 | 1 | 2 | 1 | 0 | 2 | 1 | 1 | 1 | 3 | 17 |
| Male | 7 | 2 | 2 | 4 | 5 | 6 | 4 | 5 | 1 | 5 | 5 | 46 |
| Ethnicity (NIH/OMB)(Participants) | Placebo - Part A | 3 mg LY3316531 IV - Part A | 15 mg LY3316531 IV - Part A | 75 mg LY3316531 IV - Part A | 300 mg LY3316531 IV - Part A | 300 mg LY3316531 SC- Part A | 900 mg LY3316531 IV - Part A | 2000 mg LY3316531 IV - Part A | Placebo - Part B | 2000 mg LY3316531 IV - Part B | 300 mg LY3316531 IV - Part C | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 2 | 1 | 1 | 2 | 4 | 2 | 2 | 2 | 1 | 0 | 0 | 17 |
| Not Hispanic or Latino | 9 | 2 | 2 | 4 | 2 | 4 | 4 | 4 | 1 | 6 | 8 | 46 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo - Part A | 3 mg LY3316531 IV - Part A | 15 mg LY3316531 IV - Part A | 75 mg LY3316531 IV - Part A | 300 mg LY3316531 IV - Part A | 300 mg LY3316531 SC- Part A | 900 mg LY3316531 IV - Part A | 2000 mg LY3316531 IV - Part A | Placebo - Part B | 2000 mg LY3316531 IV - Part B | 300 mg LY3316531 IV - Part C | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Black or African American | 5 | 2 | 0 | 3 | 1 | 0 | 2 | 2 | 0 | 2 | 4 | 21 |
| White | 5 | 1 | 2 | 3 | 5 | 4 | 3 | 4 | 2 | 2 | 3 | 34 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 2 | 1 | 4 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Placebo - Part A | 3 mg LY3316531 IV - Part A | 15 mg LY3316531 IV - Part A | 75 mg LY3316531 IV - Part A | 300 mg LY3316531 IV - Part A | 300 mg LY3316531 SC- Part A | 900 mg LY3316531 IV - Part A | 2000 mg LY3316531 IV - Part A | Placebo - Part B | 2000 mg LY3316531 IV - Part B | 300 mg LY3316531 IV - Part C | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | 11 | 3 | 3 | 6 | 6 | 6 | 6 | 6 | 2 | 6 | 8 | 63 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jan 2018 to primary completion in Dec 2018, 10 months.
Results were first posted in Sep 2023, 4 years 8 months after primary completion.
Of 137 industry-sponsored phase 1 interventional studies under Psoriasis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 10 months is close to that.
Counting every sponsor, half of 155 studies reached it within 10 months; a quarter within 5 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.